Brinzolamide: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Brinzolamide. Educational only — not medical advice.
Labeled uses
SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Source: FDA labeling via NIH DailyMed (set a49c157e…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.